Silence Therapeutics used its full-year earnings results this morning to unveil a phase 2 win—but also the loss of one of its partnerships. Mallinckrodt notified the British biotech earlier this month that it doesn’t plan to continue developing the siRNA drug SLN501 once an ongoing phase 1 trial has been completed, according to Silence. Source: Fierce Biotech 13/3/2024